The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).
 
Taiga Nishihori
Research Funding - Celgene (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Qaiser Bashir
Consulting or Advisory Role - Amgen; Kite, a Gilead company; Purdue Pharma; Spectrum Pharmaceuticals; Takeda
Research Funding - Acrotech Biopharma; Celgene; Stemline Therapeutics (Inst); Takeda (Inst)
 
Marcelo C. Pasquini
Honoraria - Celgene
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Medigene (Inst); Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Kite/Gilead (Inst); Novartis (Inst)
 
Michael Martens
No Relationships to Disclose
 
Juan Wu
No Relationships to Disclose
 
Melissa Alsina
Honoraria - Janssen
Consulting or Advisory Role - BMS; Janssen Oncology; oncopeptides
Speakers' Bureau - GlaxoSmithKline; Janssen Oncology
Research Funding - BMS (Inst)
 
Yvonne Adeduni Efebera
Honoraria - Takeda
Speakers' Bureau - Akcea Therapeutics; Janssen; Takeda
 
Cristina Gasparetto
Leadership - Celgene
Consulting or Advisory Role - Abbvie/Genentech; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi
Speakers' Bureau - GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
Travel, Accommodations, Expenses - Celgene; Karyopharm Therapeutics
 
Nancy Geller
No Relationships to Disclose
 
Sergio Giralt
Honoraria - Amgen; Celgene; Jazz Pharmaceuticals; Sanofi; Takeda
Consulting or Advisory Role - Actinuum; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Jazz Pharmaceuticals; Johnson & Johnson; Pfizer; Sanofi; Takeda
Research Funding - Actinuum; Amgen; Celgene (Inst); Celgene (Inst); Johnson & Johnson; Miltenyi Biotec (Inst); Sanofi; Takeda
Travel, Accommodations, Expenses - Amgen; Celgene; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Sanofi
 
John Koreth
No Relationships to Disclose
 
Philip L. McCarthy
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; The Binding Site
Consulting or Advisory Role - Bluebird Bio; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Magenta Therapeutics; Sanofi; The Binding Site
Research Funding - Celgene (Inst)
 
Emma Catherine Scott
Employment - Cytokinetics (I); GlaxoSmithKline
Stock and Other Ownership Interests - Cytokinetics (I); GlaxoSmithKline
 
Edward Allen Stadtmauer
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Sanofi; Takeda; Teva
 
David H. Vesole
Stock and Other Ownership Interests - Abbvie; Amgen; Biogen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Lilly; Merck; Novartis; Sorrento Therapeutics
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Sanofi; Takeda
 
Parameswaran Hari
Honoraria - Abbvie/Pharmacyclics; Amgen; BMS; GlaxoSmithKline; Incyte; Janssen Oncology; Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics; Sanofi; Takeda
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)